Efficacy of teicoplanin for the prevention of surgical site infections after total hip or knee arthroplasty: a prospective, open-label study

International Journal of Antimicrobial Agents

Volumn 33, Issue 5, 2009, Pages 437-440

  Kanellakopoulou, Kyriaki ^a   Papadopoulos, Antonios ^a   Varvaroussis, Dimitrios ^b   Varvaroussis, Amyntas ^b   Giamarellos Bourboulis, Evangelos J ^a   Pagonas, Athanassios ^b   Stergiou, Anestis ^b   Papadelis, Panagiotis ^b   Nikolaidis, Vassilios ^b   Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b KAT Maroussi Hospital   (Greece)

Author keywords

Arthroplasty; Prophylaxis; Surgical site infections; Teicoplanin

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; TEICOPLANIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS EPIDERMIDIS; SURGICAL INFECTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; ARTHROPLASTY; BACTERIAL INFECTIONS; CHEMOPREVENTION; CROSS INFECTION; FEMALE; FOLLOW-UP STUDIES; HIP; HUMANS; KNEE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURGICAL WOUND INFECTION; TEICOPLANIN;

EID: 62949109271     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.10.019     Document Type: Article

References (22)

1. Lindgren L. Joint prosthetic infections: a success story. Acta Orthop Scand 72 (2001) 553-556
2. Rafiq I., Gambhir A.K., Wroblewski B.M., and Kay P.R. The microbiology of infected hip arthroplasty. Int Orthop 30 (2006) 532-535
3. Edwards C., Counsell A., Boulton C., and Moran C.G. Early infection after hip fracture surgery: risk factors, costs and outcome. J Bone Joint Surg Br 90 (2008) 770-777
4. Marculescu C.E., and Cantey J.R. Polymicrobial prosthetic joint infections: risk factors and outcome. Clin Orthop Relat Res 466 (2008) 1397-1404
5. Hanssen A.D., and Osmon D.R. The use of prophylactic antimicrobial agents during and after hip arthroplasty. Clin Orthop Relat Res 369 (1999) 124-138
6. Engesaeter L.B., Lie S.A., Espehaug B., Furnes O., Vollset S.E., and Havelin L.I. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand 74 (2003) 644-655
7. Pantazatou A., Papaparaskevas J., Stefanou I., Papanicolas J., Demertzi E., and Avlamis A. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in a Greek tertiary care hospital, over an 8-year-period. Int J Antimicrob Agents 21 (2003) 542-546
8. Biedenbach D.J., Bell J.M., Sader H.S., Fritsche T.R., Jones R.N., and Turnidge J.D. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int J Antimicrob Agents 30 (2007) 143-149
9. Espehaug B., Engesaeter L.B., Vollset S.E., Havelin L.I., and Langeland N. Antibiotic prophylaxis in total hip arthroplasty. Review of 10,905 primary cemented total hip replacements reported to the Norwegian arthroplasty register, 1987 to 1995. J Bone Joint Surg Br 79 (1997) 590-595
10. de Lalla F., and Tramarin A. A risk-benefit assessment of teicoplanin in the treatment of infections. Drug Saf 13 (1995) 317-328
11. Rosina R., Villa G., Danese A., Cavenaghi L., Picardi L., and Salvadeo A. Pharmacokinetics of teicoplanin in the elderly. J Antimicrob Chemother 21 (1988) 39-45
12. Wilson A.P.R., Gruneberg R.N., and Neu H. Dosage recommendations for teicoplanin. J Antimicrob Chemother 32 (1993) 792-796
13. Widmer A. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 33 Suppl 2 (2001) S94-S106
14. Maltezou H.C., and Giamarellou H. Community-acquired methicillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents 27 (2006) 87-96
15. Marcotte A.L., and Trzeciak M.A. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen in orthopaedics. J Am Acad Orthop Surg 16 (2008) 98-106
16. Vardakas K.Z., Sotiriades E.S., Chrysanthopoulou S.A., Papagelopoulos P.S., and Falagas M.E. Perioperative anti-infective prophylaxis with teicoplanin compared to cephalosporins in orthopedic and vascular surgery involving prosthetic material. Clin Microbiol Infect 11 (2005) 775-777
17. Soriano A., Popescu D., García S., Bori G., Martínez J.A., Balasso V., et al. Usefulness of teicoplanin for preventing methicillin-resistant Staphylococcus aureus infections in orthopedic surgery. Eur J Clin Microbiol Infect Dis 25 (2006) 35-38
18. Nehrer S., Thalhammer F., Schwameis E., Breyer S., and Kotz R. Teicoplanin in the prevention of infection in total hip replacement. Arch Orthop Trauma Surg 118 (1998) 32-36
19. Lazzarini L., Novelli A., Marzano N., Timillero L., Fallani S., Viola R., et al. Regional and systemic prophylaxis with teicoplanin in total knee arthroplasty: a tissue penetration study. J Arthroplasty 18 (2003) 342-346
20. Bogdanovich T., Ednie L.M., Shapiro S., and Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 49 (2005) 4210-4219
21. Cranny G., Elliott R., Weatherly H., Chambers D., Hawkins N., Myers L., et al. A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. Health Technol Assess 12 (2008) iii-iv, xi-xii, 1-147
22. Wilson A.P. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents 10 (1998) 143-152